Acclaimed US novelist Joyce Carol Oates slams Brandeis University
Although the company will continue to pursue “higher-risk, high reward” drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. Flair also analysed dozens of open letters…